Rakovina Therapeutics Gives Replace on Beforehand Introduced Non-public Placement

Article content material

All
greenback
quantities
mirrored
in
Canadian
{dollars}
except
in any other case
acknowledged.

VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Firm”), a biopharmaceutical firm dedicated to advancing new most cancers therapies primarily based on novel DNA-damage response applied sciences, publicizes that, additional to the press releases dated Might 23, 2024, June 20, 2024 and July 19, 2024, the Firm has acquired subscriptions for an combination of $2,000,000 price of models of the Firm and has issued and closed on 19,200,000 models.

Article content material

Topic to TSX Enterprise Change approval and additional to our press launch dated July 19, 2024 asserting the upsizing of the personal placement to $2.3 million, the Firm anticipates closing on the remaining quantity beneath the personal placement by the tip of this week.

About
Rakovina
Therapeutics
Inc.
Rakovina Therapeutics Inc. is concentrated on the event of recent most cancers therapies primarily based on novel DNA-damage response applied sciences. The Firm has established a pipeline of novel DNA-damage response inhibitors with the aim of advancing a number of drug candidates into human scientific trials and acquiring advertising and marketing approval for brand new most cancers therapeutics from Well being Canada, america Meals and Drug Administration and related worldwide regulatory companies. Additional info could also be discovered at www.rakovinatherapeutics.com.

The
TSX-V
has
neither
authorized
nor
disapproved
the
content material
of
this
press
launch.
Neither
the TSX-V nor its Regulation Companies Supplier (as that time period is outlined in insurance policies of the TSX-V) accepts duty for the adequacy or accuracy of this launch.

Article content material

Article content material

Discover
Relating to
Ahead-Trying
Statements:
This launch consists of forward-looking statements relating to the Firm and its respective enterprise, which
could
embrace, however is
not
restricted
to,
statements with
respect
to the timeline of
the personal placement, TSX Enterprise Change approval for the upsizing, the proposed marketing strategy of the Firm and different statements. Typically, however not all the time, forward-looking statements might be recognized by way of phrases similar to “plans”, “is anticipated”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (together with adverse variations) of such phrases and phrases, or state that sure actions, occasions, or outcomes “could”, “may”,
“would”,
“may”
or
“will” be
taken,
happen
or
be
achieved.
Such statements
are
primarily based
on the present expectations of the administration of the Firm. The forward-looking occasions and circumstances mentioned on this launch could not happen by sure specified dates or in any respect and will differ
materially as
a outcome
of
identified
and unknown threat
components
and
uncertainties
affecting the Firm, together with dangers relating to the medical system trade, financial components, regulatory components and the necessity for regulatory approval, the fairness markets typically and dangers related to development and competitors.

Article content material

Though the Firm has tried to establish necessary components that might trigger precise actions, occasions, or outcomes to vary materially from these described in forward-looking statements,
there
could
be
different
components
that
trigger
actions,
occasions,
or
outcomes
to
differ
from
these anticipated,
estimated
or
meant.
No
forward-looking
assertion
can
be
assured.
Besides
as required by
relevant securities legal guidelines,
forward-looking statements
converse solely as of
the date on which they’re made and the Firm undertakes no obligation to publicly replace or revise any forward-looking assertion, whether or not because of new info, future occasions, or in any other case.
The reader is referred to the Firm’s most up-to-date filings on SEDAR for a extra full
dialogue
of
all
relevant
threat
components
and
their
potential
results,
copies
of
which
could also be accessed by the Firm’s profile web page at www.sedar.com.

For Additional Data Contact: David Hyman, Chief Monetary Officer data@rakovinatehrapeutics.com

Investor Relations & Media Ira M. Gostin ir@rakovinatherapeutics.com 775-391-0213

Article content material